Genome editing of TGFBI in human ABCG2+/ABCB5+ double-positive LESCs by CRISPR/Cas9 may be useful strategy to treat corneal dystrophy, and these new tools may not only facilitate the identification of both the cellular function of TGFBI and signaling pathways critical for corneal dystrophy diseases but also provide new treatment options for patients suffering from this disease. This evidence concerns the gene TGFBI and corneal dystrophy.